blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2247300

EP2247300 - MNTF PEPTIDE COMPOSITIONS AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.02.2017
Database last updated on 08.10.2024
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Genervon Biopharmaceuticals LLC
1055 E. Colorado Blvd.
Suite 500
Pasadena, CA 91106 / US
[2016/08]
Former [2010/45]For all designated states
Genervon Biopharmaceuticals LLC
830 North Wilcox Avenue
Montebello, CA 90640 / US
Inventor(s)01 / KO, Pui-yuk, Dorothy
1030 De La Fuente Street
Monterey Park, CA 91754 / US
02 / KINDY, Mark, S.
3384 Shagbark Circle
Mt. Pleasant, SC 29466 / US
 [2010/45]
Representative(s)Casley, Christopher Stuart, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[2016/15]
Former [2010/45]Casley, Christopher Stuart, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Application number, filing date09712319.423.02.2009
[2010/45]
WO2009US34923
Priority number, dateUS2008006666921.02.2008         Original published format: US 66669
[2010/45]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009105780
Date:27.08.2009
Language:EN
[2009/35]
Type: A2 Application without search report 
No.:EP2247300
Date:10.11.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 27.08.2009 takes the place of the publication of the European patent application.
[2010/45]
Type: B1 Patent specification 
No.:EP2247300
Date:13.04.2016
Language:EN
[2016/15]
Search report(s)International search report - published on:EP05.11.2009
ClassificationIPC:A61K38/17, A61K38/18, C07K14/475
[2010/45]
CPC:
C07K14/475 (EP,US); A61P25/00 (EP); A61K38/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/15]
Former [2010/45]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:MNTF-PEPTID-ZUSAMMENSETZUNGEN UND ANWENDUNGSVERFAHREN[2010/45]
English:MNTF PEPTIDE COMPOSITIONS AND METHODS OF USE[2010/45]
French:COMPOSITIONS DE FACTEURS MOTONEUROTROPHIQUES ET PROCÉDÉS D'UTILISATION DE CES PEPTIDES[2010/45]
Entry into regional phase09.09.2010National basic fee paid 
09.09.2010Designation fee(s) paid 
09.09.2010Examination fee paid 
Examination procedure18.12.2009Request for preliminary examination filed
International Preliminary Examining Authority: EP
09.09.2010Examination requested  [2010/45]
08.11.2010Amendment by applicant (claims and/or description)
17.12.2012Despatch of a communication from the examining division (Time limit: M06)
21.05.2013Reply to a communication from the examining division
21.11.2013Observations by third parties
04.12.2013Despatch of a communication from the examining division (Time limit: M04)
24.03.2014Reply to a communication from the examining division
15.04.2014Despatch of a communication from the examining division (Time limit: M04)
21.08.2014Reply to a communication from the examining division
04.02.2015Despatch of a communication from the examining division (Time limit: M04)
30.03.2015Reply to a communication from the examining division
26.08.2015Communication of intention to grant the patent
22.12.2015Receipt of the translation of the claim(s)
23.12.2015Fee for grant paid
23.12.2015Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.12.2012
Opposition(s)16.01.2017No opposition filed within time limit [2017/12]
Fees paidRenewal fee
21.02.2011Renewal fee patent year 03
20.02.2012Renewal fee patent year 04
20.02.2013Renewal fee patent year 05
24.02.2014Renewal fee patent year 06
24.02.2015Renewal fee patent year 07
24.02.2016Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.02.2009
BG13.04.2016
CY13.04.2016
CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
MC13.04.2016
MK13.04.2016
PL13.04.2016
RO13.04.2016
SI13.04.2016
SK13.04.2016
TR13.04.2016
NO13.07.2016
GR14.07.2016
IS13.08.2016
PT16.08.2016
[2020/33]
Former [2020/15]HU23.02.2009
BG13.04.2016
CY13.04.2016
CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
MC13.04.2016
MK13.04.2016
PL13.04.2016
RO13.04.2016
SI13.04.2016
SK13.04.2016
TR13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2019/51]HU23.02.2009
BG13.04.2016
CY13.04.2016
CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
MC13.04.2016
MK13.04.2016
PL13.04.2016
RO13.04.2016
SI13.04.2016
SK13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2019/46]HU23.02.2009
BG13.04.2016
CY13.04.2016
CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
MC13.04.2016
PL13.04.2016
RO13.04.2016
SI13.04.2016
SK13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2019/39]HU23.02.2009
BG13.04.2016
CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
MC13.04.2016
PL13.04.2016
RO13.04.2016
SI13.04.2016
SK13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2019/31]HU23.02.2009
CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
MC13.04.2016
PL13.04.2016
RO13.04.2016
SI13.04.2016
SK13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2017/47]CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
MC13.04.2016
PL13.04.2016
RO13.04.2016
SI13.04.2016
SK13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2017/37]CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
PL13.04.2016
RO13.04.2016
SI13.04.2016
SK13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2017/10]CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
PL13.04.2016
RO13.04.2016
SK13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2017/09]CZ13.04.2016
EE13.04.2016
HR13.04.2016
LT13.04.2016
LV13.04.2016
PL13.04.2016
RO13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2016/51]HR13.04.2016
LT13.04.2016
LV13.04.2016
PL13.04.2016
NO13.07.2016
GR14.07.2016
PT16.08.2016
Former [2016/49]LT13.04.2016
PL13.04.2016
NO13.07.2016
Former [2016/46]LT13.04.2016
NO13.07.2016
Cited inInternational search[I]WO2007058982  (GENERVON BIOPHARMACEUTICALS LLC [US], et al) [I] 1,3,10-17 * the whole document *;
 [I]US2006052299  (CHAU RAYMOND M W [CN], et al) [I] 1,3,10-17 * the whole document *;
 [Y]WO2004065410  (GENERVON BIOPHARMACEUTICALS LLC [US], et al) [Y] 1,3,10-17 * the whole document *;
 [Y]US2002086831  (CHAU RAYMOND MING WAH [HK]) [Y] 1,3,10-17 * the whole document *
Examination   - GOSALINA DHAVAL N ET AL, "Functional phenotyping of human plasma using a 361-fluorogenic substrate biosensing microarray", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, (20060801), vol. 94, no. 6, ISSN 0006-3592, pages 1099 - 1110, XP002450743
otherAU2009217266
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.